Transcode Therapeutics, INC. (RNAZ) — 10-Q Filings

10-Q Filings (6)

• Transcode's Net Loss Nearly Doubles Amidst Warrant Revaluation, Strategic Acquisition — Nov 14, 2025 Risk: high
  Transcode Therapeutics, Inc. (RNAZ) reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $(21,217,966) compared to
• Transcode's Net Loss Widens to $16.36M Amid Warrant Revaluation — Aug 14, 2025 Risk: high
  Transcode Therapeutics, Inc. (RNAZ) reported a significant increase in net loss for the six months ended June 30, 2025, reaching $16,361,915, a substantial rise
• Transcode Therapeutics Q1 2025 10-Q Filed — May 14, 2025 Risk: medium
  Transcode Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported total assets of $1,029,095 and total liabilities of $2,33
• Transcode Therapeutics Files Q3 2024 10-Q — Nov 14, 2024 Risk: medium
  Transcode Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported financial results and provided updates on its busines
• Transcode Therapeutics Q2 2024 Update — Aug 14, 2024 Risk: medium
  Transcode Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported cash and cash equivalents of $7.27 million. The filing det
• Transcode Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024 — May 15, 2024 Risk: medium
  Transcode Therapeutics, Inc. (RNAZ) filed a Quarterly Report (10-Q) with the SEC on May 15, 2024. Transcode Therapeutics, Inc. reported financial results for th

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX